The HIV diagnosis market is projected to reach USD 3.88 Billion by 2021 from USD 2.35 Billion in 2016, at a CAGR of 10.5% from 2016 to 2021. Factors such as the growing worldwide prevalence of HIV/AIDS, increasing number of blood transfusions and blood donations, benefits offered by point-of-care instruments and kits, and increasing government initiatives are expected to drive the growth of the market worldwide. The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=66008285
The major players in the HIV diagnosis market are Siemens AG (Germany), Roche Diagnostics (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Thermo-Fisher Scientific Inc. (US), Merck KGaA (Germany), Becton, Dickinson and Company (US), Hologic, Inc. (US), Alere Inc. (US), and Bio-Rad Laboratories (US).
This market is segmented based on products, test types, end user, and region. On the basis of product, the market is segmented into consumables (assays, kits, reagents, and other consumables), instruments, and software and services. In 2016, the consumables segment is expected to account for the largest share of the market. The frequent and repetitive purchase of consumables by laboratories and hospitals, growing prevalence of HIV/AIDS, and increasing initiatives from governments to fight HIV/AIDS are some of the major factors driving the consumables market.
On the basis of test type, the market is segmented into antibody tests, viral load tests, CD4 count tests, tests for early infant diagnosis, and tests for viral identification. The antibody tests segment is further divided into HIV-1 screening tests, HIV-1 confirmatory tests, and HIV-2 and group O diagnostic tests. The antibody tests segment is expected to account for the largest share of the market in 2016. This large share can be attributed to the increasing technological advancements in HIV diagnosis, growing awareness about HIV, and rising blood donations.
On the basis of end user, the HIV diagnosis market is divided into diagnostic laboratories, hospitals, blood banks, home care settings, and others (gene banks, cell banks, biotechnology and pharmaceutical companies, and academic research institutes). The diagnostic laboratories segment is expected to account for the largest share of market in 2016. This large share is mainly due to high investment and technological advancements of diagnostics laboratories. It is also driven by increasing awareness of HIV/AIDS.